Sit Investment Associates’s Ascendis Pharma A/S ASND Stock Holding History

Sit Investment Associates’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.24M	Sell	15,900 -4,195	-21%	-$980K	0.08%	219
2026 Q1	$4.6M	Hold	20,095	–	–	0.09%	207
2025 Q4	$4.29M	Hold	20,095	–	–	0.08%	215
2025 Q3	$4M	Buy	20,095 +690	+4%	+$129K	0.08%	224
2025 Q2	$3.35M	Hold	19,405	–	–	0.07%	244
2025 Q1	$3.02M	Hold	19,405	–	–	0.07%	262
2024 Q4	$2.67M	Hold	19,405	–	–	0.06%	287
2024 Q3	$2.9M	Buy	19,405 +6,525	+51%	+$881K	0.06%	269
2024 Q2	$1.76M	Buy	+12,880	New	+$1.75M	0.04%	308

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Sit Investment Associates's ASND Position: Q2 2026 in Review

Sit Investment Associates reduced its Ascendis Pharma A/S (ASND) stake by 21% in Q2 2026, selling an estimated $980K and leaving 15,900 shares worth $4.24M. The position accounts for 0.08% of the portfolio, ranked #219.

Sit Investment Associates first reported a position in ASND in Q2 2024 and has held it in 9 quarters since. The position peaked at $4.6M in Q1 2026. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Sit Investment Associates held 15,900 shares of Ascendis Pharma A/S worth $4.24M as of Q2 2026.
Sit Investment Associates sold 4,195 Ascendis Pharma A/S shares in Q2 2026, an estimated $980K.
Ascendis Pharma A/S made up 0.08% of Sit Investment Associates's portfolio in Q2 2026, its #219 holding.
Sit Investment Associates first reported a position in Ascendis Pharma A/S in Q2 2024 and has held it in 9 quarters since.
Sit Investment Associates's Ascendis Pharma A/S position peaked at $4.6M in Q1 2026.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Sit Investment Associates's 13F filing for Q2 2026, filed 12 Aug 2026.